Gabapentin significantly improves cough symptoms in idiopathic pulmonary fibrosis (IPF) patients compared to placebo with a substantial increase in cough relief rate.
The safety profile of gabapentin in IPF cough includes manageable adverse effects such as drowsiness and dizziness, occurring in approximately one-third of treated patients.
These findings align with CHEST expert panel suggestions endorsing neuromodulators like gabapentin for refractory cough in interstitial lung disease (ILD), addressing an unmet therapeutic need.
Background
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
